The April 2026 study from Ben-Gurion University and Soroka University Medical Center, published in Sleep and Breathing, reports that adults with obstructive sleep apnea (OSA) exhibit significantly lower skeletal muscle density and elevated skeletal muscle index on CT imaging compared to controls. This observational retrospective analysis leveraged existing CT scans to assess muscle composition and bone parameters without added radiation burden. While sample size is not explicitly detailed in the press materials, the collaboration with the Department of Epidemiology suggests a sizable clinical cohort drawn from routine care databases. No conflicts of interest were declared.

This builds directly on the team’s prior 2025 Scientific Reports paper that linked OSA to reduced bone mineral density, forming an emerging body of evidence on under-appreciated skeletal sequelae. What the MedicalXpress coverage and university release miss, however, is the mechanistic depth and broader aging context. Chronic intermittent hypoxia and sleep fragmentation in OSA drive systemic inflammation, oxidative stress, and insulin resistance—pathways known to promote myosteatosis (fat infiltration of muscle, reflected in lower CT density) and impair osteoblast function. These processes accelerate sarcopenia and osteoporosis, two hallmarks of frailty that extend far beyond the cardiovascular and neurocognitive risks typically highlighted in OSA literature.

Synthesizing additional peer-reviewed sources strengthens this picture. A 2022 systematic review and meta-analysis in Osteoporosis International (encompassing 12 observational studies, >500,000 participants) found OSA associated with a 1.6-fold increased risk of vertebral and hip fractures, with stronger associations in untreated moderate-to-severe cases. Another 2023 meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle (15 studies, n≈28,000) reported consistent links between OSA and sarcopenic indices, particularly in adults over 60, though most data remain cross-sectional and cannot prove causation. The Ben-Gurion work adds valuable imaging-derived muscle quality metrics that earlier questionnaire-based studies lacked.

The original coverage also underplays effect modification by age, sex, and comorbidities. Post-menopausal women and older men appear especially vulnerable because OSA compounds the natural decline in sex hormones that protect muscle and bone. This fits larger patterns in geriatric medicine where sleep disorders are overlooked modifiable drivers of frailty, alongside physical inactivity and poor nutrition. Preventive wellness frameworks have historically prioritized cardiovascular screening for OSA patients; the skeletal dimension demands equal attention. Routine opportunistic screening of CT-derived muscle and bone indices—already performed for other indications—represents low-cost, high-yield secondary prevention.

Important caveats remain. As an observational study, residual confounding by obesity, physical activity levels, or vitamin D status cannot be fully excluded. Whether CPAP or other OSA therapies can reverse these muscle and bone changes is still unclear; small RCTs have shown modest improvements in muscle strength after 6–12 months, yet long-term fracture-reduction trials are absent.

Prof. Tarasiuk’s warning is apt: untreated OSA threatens independence in later life. The real story is that skeletal impacts may represent an underreported accelerant of biological aging. Integrating sleep medicine, radiology, and gerontology could shift OSA management from reactive treatment of daytime sleepiness to proactive preservation of musculoskeletal health. Future prospective studies must quantify whether early intervention alters trajectories of frailty, but current evidence already justifies expanded CT screening protocols and heightened clinical vigilance.